DrugPatentWatch Database Preview
Drugs in Development Information for RRx-001
» See Plans and Pricing
What is the drug development status for RRx-001?
RRx-001 is an investigational drug.
There have been 12 clinical trials for RRx-001.
The most recent clinical trial was a Phase 1 trial, which was initiated on November 1st 2018.
The most common disease conditions in clinical trials are Neoplasm Metastasis, Brain Neoplasms, and Neoplasms. The leading clinical trial sponsors are EpicentRx, Inc., Texas Children's Cancer Center, and Drais Pharmaceuticals, Inc.
There are seven US patents protecting this investigational drug and thirty-eight international patents.
Summary for RRx-001
| US Patents | 7 |
| International Patents | 38 |
| US Patent Applications | 10 |
| WIPO Patent Applications | 13 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 1 (2018-11-01) |
| Vendors | 31 |
Recent Clinical Trials for RRx-001
| Title | Sponsor | Phase |
|---|---|---|
| RRx-001 Given With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System Tumors | Texas Children's Cancer Center | Phase 1 |
| RRx-001 Given With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System Tumors | EpicentRx, Inc. | Phase 1 |
| RRx-001 Prior to a Platinum Doublet or a Platinum Doublet Alone in Patients With Small Cell Carcinoma | EpicentRx, Inc. | Phase 3 |
Clinical Trial Summary for RRx-001
Top disease conditions for RRx-001
Top clinical trial sponsors for RRx-001
US Patents for RRx-001
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| RRx-001 | Start Trial | Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof | RadioRx, Inc. (Menlo Park, CA) Alliant Techsystems Inc. (Edina, MN) | Start Trial |
| RRx-001 | Start Trial | Methods of synthesizing cyclic nitro compounds | Alliant Techsystems Inc. (Minneapolis, MN) | Start Trial |
| RRx-001 | Start Trial | Methods of synthesizing cyclic nitro compounds | Alliant Techsystems Inc. (Arlington, VA) | Start Trial |
| RRx-001 | Start Trial | Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof | RadioRx, Inc. (Menlo Park, CA) Alliant Techsystems Inc. (Minneapolis, MN) | Start Trial |
| RRx-001 | Start Trial | Methods of synthesizing and isolating N-(bromoacetyl)-3,3-dinitroazetidine and a composition including the same | Alliant Techsystems Inc. (Arlington, VA) | Start Trial |
| RRx-001 | Start Trial | Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof | EpicentRx, Inc. (Mountain View, CA) Alliant Techsystems Inc. (Minneapolis, MN) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for RRx-001
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| RRx-001 | Australia | AU2006279589 | 2025-08-12 | Start Trial |
| RRx-001 | Canada | CA2620612 | 2025-08-12 | Start Trial |
| RRx-001 | China | CN101370492 | 2025-08-12 | Start Trial |
| RRx-001 | Cyprus | CY1116094 | 2025-08-12 | Start Trial |
| RRx-001 | Denmark | DK1924253 | 2025-08-12 | Start Trial |
| RRx-001 | European Patent Office | EP1924253 | 2025-08-12 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
